Investors & Media

Investors & Media

Welcome to our investor page

We aspire to individualize cancer medicine

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.


Stock Quote

Nov 27, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events

More events are coming soon.

Press Releases

25 November 2020

BioNTech und InstaDeep geben strategische Partnerschaft bekannt und gründen AI ..

20 November 2020

Pfizer und BioNTech reichen Antrag auf Notfallzulassung für COVID-19-Impfstoff ..

18 November 2020

Pfizer und BioNTech schließen Phase-3-Studie erfolgreich ab: Impfstoffkandidat ..